CaMaRa

CaMaRa is a biotechnology company developing new medicines for cardiometabolic conditions, including obesity, diabetes and kidney disease.

In collaboration with the Broad Institute of MIT and Harvard, CaMaRa studies how disease-linked genetic differences affect specific genes, cells and disease- specific tissues.

The company combines these insights with its proprietary AI-driven Target Assessment Framework to select the most promising drug targets. CaMaRa then acquires advanced drug candidates designed to act on those targets, providing a faster route to clinical evaluation and proof proof-of of-concept.